Biotechs target rare cancers to find lucrative markets

10/28/2005 | Forbes

Ariad Pharmaceuticals, like many biotech firms, once pursued drugs only for the largest markets but now is testing a drug, AP23573, aimed at a rare form of sarcoma diagnosed in only 12,000 to 13,000 patients a year. Other boutique firms focusing on rare disease are finding the cause may be narrowed to a single gene and the results can be successful and profitable when few other remedies exist.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC